Drug Trial Radar · NCT06630260
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
182
Planned (sponsor's estimate)
Start
Nov 15, 2024
Primary completion
Sep 30, 2029
Study completion Sep 30, 2030
Sponsor
- Lead sponsor
- Institute of Cancer Research, United KingdomAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Minderoo Foundation; Verastem, Inc.; Royal Marsden NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cancer Research UK; University of Cambridge
- First posted
- Oct 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the safety and tolerability of avutometinib and defactinib and to determine the preliminary antitumour activity of avutometinib and defactinib administered at the recommended Phase 2 dose (RP2D). In the Phase 1b of this study parallel biomarker defined arms will be opened, initially in the relapsed GMB setting, enrolling 12 patients onto each arm. These patients will be treated with avutometinib and defactinib double therapy. Avutometinib will be administered orally at 3.2mg twice a week (e.g., on Monday / Thursday or Tuesday / Friday) with or without a meal. The total weekly dose of avutometinib is 6.4mg. Defactinib will be administered orally, at 200mg, twice a day within 30 min after a meal. The total daily dose of defactinib is 400mg. Once a treatment in any biomarker arm has met the "GO" decision (≥3 successes/12 patients) for relapsed GBM in Phase 1b, that arm can progress to Phase 2. The primary objective of Phase 2 is to determine the antitumour activity of investigational agents administered at the RP2D in patients with molecularly defined malignant brain tumours.
Conditions
- Glioblastoma Multiforme (GBM)
- Glioblastoma Multiform (Grade IV Astrocytoma)
- Diffuse Hemispheric Glioma, H3 G34-Mutant
- Malignant Primary Gliomas
Interventions
AvutometinibDrug
Supplied as 0.8mg capsules.
DefactinibDrug
Supplied as 200mg tablets.
TemozolomideDrug
Temozolomide will be supplied as 5, 20, 100, 140, 180 or 250 mg hard capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b - To evaluate the safety and tolerability of investigational agent in patients with malignant brain tumoursTime frame: 12 months
- Phase 1b - To determine the preliminary antitumour activity of the investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumoursTime frame: 12 months
- Phase 2 - To determine the antitumour activity of investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumoursTime frame: 9 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Cambridge University Hospitals
Cambridge, United Kingdom · Recruiting
The Royal Marsden Hospital - Drug Development Unit
Sutton, United Kingdom · Recruiting
The Royal Marsden Hospital - Neuro-Oncology Unit
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.